Navigation Links
Elka Nir Joins VisionCare Board of Directors
Date:2/5/2011

SARATOGA, Calif., Feb. 5, 2011 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of end-stage age-related macular degeneration, today announced Elka Nir of Giza Venture Capital has joined VisionCare's Board of Directors. Ms. Nir expands the company's Board to seven.

Ms. Nir heads the life sciences sector for Giza and serves on the board of directors of five medical device companies in Israel and the US. Prior to Giza, she led large multi-disciplinary teams (R&D, supply chain, quality & regulatory, marketing) at a division of Johnson & Johnson managing multi-million dollar budgets and delivering innovative market leading products, resulting in over $400 million in yearly revenues and double-digit annual growth.

Ms. Nir holds a B.Sc. in Computer Science, from Technion-Israel Institute of Technology, Haifa, Israel, a B.S. from the University of Haifa, and completed the Senior Executive Education program at Stanford University School of Business.

Allen W. Hill, VisionCare's President and CEO, commented, "VisionCare welcomes Elka to our Board. She was instrumental in helping VisionCare raise $31.4 million in the recent Series E financing. Elka's extensive experience in executive roles and raising funds for the development of new state of the art solutions, via business collaboration with global market leaders, will be of great assistance to VisionCare."

On joining the VisionCare Board, Elka Nir commented, "VisionCare has made tremendous progress in developing, clinically testing, and obtaining FDA approval for its implantable telescope prosthesis in patients with advanced forms of macular degeneration, which disables hundreds of thousands of individuals in major markets. VisionCare's products show significant promise of improving vision and quality of life for these individuals who now have no other surgical option. I am looking forward to working with the Board and the company as it begins US commercialization of this breakthrough product later this year."  

About the Telescope Implant

The Implantable Miniature Telescope (by Dr. Isaac Lipshitz) is designed to improve vision and quality of life in patients with end-stage AMD.  Smaller than a pea, the telescope is implanted in one eye in an outpatient surgical procedure.

CentraSight Treatment Program

The first-of-kind telescope implant is integral to a new patient care program, CentraSight, for treating patients with end-stage AMD. The CentraSight treatment program involves a patient management process and access to reimbursement resources for patients and physicians. Patients and physicians can find more information about the telescope implant and related treatment program at www.centrasight.com.

About End-Stage Macular Degeneration

AMD is a disorder of the central retina, or macula, which is responsible for detailed vision that controls important functional visual activities like recognizing faces and watching television. The National Eye Institute estimates that over 1.7 million Americans over age 50 suffer vision loss from advanced AMD, which frequently culminates as end-stage AMD (visual impairment due to untreatable advanced AMD in both eyes). These patients often experience a loss of independence and quality of life, and have difficulty with activities of daily living. Approximately half of the individuals living with advanced AMD are affected in both eyes.

About Giza Venture Capital

Located in Tel Aviv, Giza is a leading venture capital firm investing in seed and early-stage technology companies.  Giza currently manages five funds totaling $600 million.  Founded in 1992, the firm's professionals have extensive experience and expertise in life sciences, communications, semiconductor, information technology, enterprise software, clean tech, media, and entertainment sectors.  Giza has invested in ninety-seven companies with thirty-two successful exits.  Information on Giza can be found at www.gizavc.com.

About VisionCare

VisionCare Ophthalmic Technologies, Inc., headquartered in Saratoga, CA, with facilities in Petah Tikva, Israel, is a privately-held company focused on the development, manufacturing, and marketing of implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders.  VisionCare's Implantable Miniature Telescope was invented by company founders Yossi Gross and Dr. Isaac Lipshitz.  Information on VisionCare can be found at www.visioncareinc.net and www.centrasight.com.


'/>"/>
SOURCE VisionCare Ophthalmic Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
2. Six Sigma Black Belt and Lean Sensei Ben Wittich Joins REMCON Plastics
3. DSM Joins International Response to Flooding in Australia
4. Ampac Fine Chemicals President Aslam Malik Joins SOCMAs Board of Governors; Industry Veteran Adds Significant Experience to Board
5. Former FDA Commissioner Joins Bexion Pharmaceuticals Board
6. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
7. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as COO
8. Joseph Perrone Joins SRI International to Direct Molecular Diagnostics and Rare and Neglected Diseases Group
9. Joseph J. LaRosa Joins Nycomed US Inc.
10. Timothy T. Goodnow, Ph.D., Joins Sensors for Medicine and Science, Inc. Board of Directors
11. Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):